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Complement and coagulation 
cascades activation is the main 
pathophysiological pathway 
in early‑onset severe preeclampsia 
revealed by maternal proteomics
Lina Youssef1, Jezid Miranda1, Miquel Blasco2, Cristina Paules1, Francesca Crovetto1, 
Marta Palomo3,4,5, Sergi Torramade‑Moix4, Héctor García‑Calderó6,7, Olga Tura‑Ceide8,9,10, 
Ana Paula Dantas11, Virginia Hernandez‑Gea6,7, Pol Herrero12, Nuria Canela12, 
Josep Maria Campistol2,13, Joan Carles Garcia‑Pagan6,7, Maribel Diaz‑Ricart4,5, 
Eduard Gratacos1,13,14* & Fatima Crispi1,13
Preeclampsia is a pregnancy‑specific multisystem disorder and a leading cause of maternal and 
perinatal morbidity and mortality. The exact pathogenesis of this multifactorial disease remains 
poorly defined. We applied proteomics analysis on maternal blood samples collected from 14 singleton 
pregnancies with early‑onset severe preeclampsia and 6 uncomplicated pregnancies to investigate 
the pathophysiological pathways involved in this specific subgroup of preeclampsia. Maternal blood 
was drawn at diagnosis for cases and at matched gestational age for controls. LC–MS/MS proteomics 
analysis was conducted, and data were analyzed by multivariate and univariate statistical approaches 
with the identification of differential pathways by exploring the global human protein–protein 
interaction network. The unsupervised multivariate analysis (the principal component analysis) 
showed a clear difference between preeclamptic and uncomplicated pregnancies. The supervised 
multivariate analysis using orthogonal partial least square discriminant analysis resulted in a model 
with goodness of fit  (R2X = 0.99, p < 0.001) and a strong predictive ability  (Q2Y = 0.8, p < 0.001). By 
univariate analysis, we found 17 proteins statistically different after 5% FDR correction (q‑value < 
0.05). Pathway enrichment analysis revealed 5 significantly enriched pathways whereby the activation 
of the complement and coagulation cascades was on top (p = 3.17e−07). To validate these results, 
we assessed the deposits of C5b‑9 complement complex and on endothelial cells that were exposed 
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to activated plasma from an independent set of 4 cases of early‑onset severe preeclampsia and 4 
uncomplicated pregnancies. C5b‑9 and Von Willbrand factor deposits were significantly higher in early‑
onset severe preeclampsia. Future studies are warranted to investigate potential therapeutic targets 
for early‑onset severe preeclampsia within the complement and coagulation pathway.
Preeclampsia is a pregnancy-specific multisystem disorder, defined as new-onset elevated blood pressure accom-
panied by proteinuria after 20 weeks of gestation. It complicates 2–5% of  pregnancies1 and is a leading cause 
of maternal and perinatal morbidity and  mortality2,3. The exact pathogenesis of preeclampsia remains poorly 
defined. Disturbed placental function has long been associated with  preeclampsia4,5. However, many other fac-
tors could play a role in preeclampsia evolution like maternal cardiovascular  maladaptation6,7, angiogenic factors 
 imbalance8 and oxidative stress. This multifactorial nature of preeclampsia explains partially its variable clinical 
presentation, ranging from mild cases that could be missed to very severe cases with a high risk of maternal 
or fetal death. Early-onset preeclampsia is less common than its late counterpart, however it is the most severe 
form that accumulates the majority of maternal and perinatal  complications9. Due to the lack in understanding 
the pathophysiology of preeclampsia, there is no available specific treatment for this disease. The only current 
“cure” for preeclampsia is the delivery, which could be an acceptable choice for late-onset preeclampsia near 
term. Whereas, in early-onset cases, it is still a real challenge to balance the risk of severe maternal complications 
when continuing the pregnancy against the fetal prematurity risk when the decision is pregnancy termination. 
Thus, there is a clinical necessity for a treatment based on understanding the pathophysiology of early-onset 
preeclampsia to delay its evolution to a severe disease and postpone the need for iatrogenic preterm delivery.
Investigating biological processes in the maternal blood could help in better understanding the pathophysiol-
ogy and identifying therapeutic targets for early-onset severe preeclampsia. In fact, proteins are essential parts 
and participate in virtually every process in the human  body10. Proteomics techniques represent a strategy 
towards high-throughput analysis of the global set of  proteins11. Recent reports have described the physiological 
pathways of interest for normal pregnancy adaptations through the  gestation12,13. Though, applying proteomics 
analysis has the potential to detect maladaptation pathways associated with preeclampsia. In the last decade, few 
studies were conducted to explore the proteomic fingerprint of preeclampsia in maternal blood near  delivery14–20, 
however their results are difficult to interpret due to including heterogenous cases of mild and severe preec-
lampsia as well as early and late-onset forms of this disorder. We hypothesized that focusing on a well-defined 
subgroup of early-onset severe preeclampsia may detect better the pathophysiological pathways involved in this 
subgroup by applying maternal blood proteomics. Thus, the aim of this study was to identify proteomic pat-
terns associated with potential pathways that play a role in the pathogenesis of early-onset severe preeclampsia.
Results
Baseline and perinatal characteristics of the study population. Baseline characteristics and 
perinatal outcomes of the study populations are shown in Table 1. The study groups were similar in terms of 
maternal baseline characteristics. None of the 3 preeclamptic pregnancies achieved by assisted reproductive 
technologies involved ovum donation. As expected, preeclamptic pregnancies presented altered feto-placental 
Doppler parameters with significantly higher levels of creatinine, urea and uric acid compared to controls. Mean 
gestational age at delivery was 32 weeks in preeclampsia group with high rate (up to 80%) of cesarean sections 
and 100% admissions to the neonatal intensive care unit presenting subsequently one case of neonatal mortal-
ity. Hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome has been diagnosed in two cases of 
preeclamptic pregnancies.
Proteomics results. Out of 273 proteins identified, 158 were present in ≥ 70% of the samples (complete 
results dataset is provided in Supplementary Data). The principal component analysis (PCA) shown in Fig. 1a,b 
demonstrates the separation between preeclampsia and uncomplicated pregnancies. The first and second com-
ponents explained 16.6% and 14% of the variance between cases and controls respectively (The main proteins 
involved in each component are provided in Supplementary Data). The partial least squares discriminant analy-
sis (PLS-DA) analysis resulted in a clear separation between the groups (Fig. 1c). The top 15 most important 
proteins contributing to class separation are shown in Fig. 1d ranked by their contribution to distinguishing 
preeclampsia from controls. The greater the distance from the Y-axis, the greater is the contribution of a par-
ticular protein. The heatmap on the right side of this plot also indicates whether this protein’s concentration 
is increased or decreased in preeclampsia relative to controls. The model obtained by orthogonal projection 
to latent structures discriminant analysis (OPLS-DA) analysis showed a high goodness of fit  (R2X = 0.995, p 
= 0.001) and a strong predictive ability  (Q2Y = 0.797, p < 0.001, 1 predictive + 2 orthogonal components) i.e. 
the model explains more than 99% of the variation between the study groups with a predictive ability of 80%). 
HELLP cases did not cluster differently to other cases of preeclampsia.
A total of 17 proteins were statistically different between the study groups by univariate analysis (Table 2), 
showing a good agreement with the multivariate results. Hierarchical clustering analysis (HCA) analysis consider-
ing these top 17 proteins showed 2 clusters corresponding to the study groups (Fig. 2a). The network generated 
using the 17 significant proteins is shown in Fig. 2b. Protein–protein interaction (PPI) enrichment p-value was 
< 1.62e−14 indicating that these proteins are not random. Pathway enrichment analysis revealed 5 significantly 
enriched pathways as shown in Table 3, the complement and coagulation cascades pathway was on top includ-
ing 5 proteins (Fig. 3).
The endothelial cells that were exposed to activated plasma from early-onset severe preeclampsia showed 
significantly higher deposits of C5b-9 complement complex and Von Willbrand factor (VWF) compared to 
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controls, which reflects the activation of the complement and coagulation cascades in these patients and its effect 
on endothelial cells (Figs. 4, 5).
Discussion
This study demonstrates the distinct maternal serum proteomic fingerprint in early-onset severe preeclampsia 
in comparison to uncomplicated pregnancies. This is the first study to show a wide set of circulating proteins 
and associated pathophysiological pathways which could provide potential therapeutic targets in this specific 
phenotype of preeclampsia.
The main differential pathway in early-onset severe preeclampsia was the complement and coagulation 
cascades activation. In addition, platelets activation was also significantly marked in this specific group of 
Table 1.  Maternal, fetal and perinatal characteristics of the study population. Data are presented as mean ± 
standard deviation, median (interquartile range) or n (%) as appropriate. BMI body mass index, PI pulsatility 
index, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma glutamyl transferase. P 




N = 14 p value
Maternal characteristics
Age (years) 36.5 ± 2.9 34.1 ± 3.8 0.28*
Caucasian ethnicity 5 (83.3) 6 (42.9) 0.10ƒ
Pre-gestational BMI (kg/m2) 22.2 ± 2.7 24.1 ± 4.1 0.38*
Nulliparity 5 (83.3) 9 (64.3) 0.39ƒ
Previous preeclampsia 0 (0) 1 (7.1) 0.50ƒ
Chronic hypertension 0 (0) 1 (7.1) 0.50ƒ
Assisted reproductive technologies 0 (0) 3 (21.4) 0.22ƒ
Smoking during pregnancy 1 (16.7) 1 (7.1) 0.52ƒ
Fetal ultrasound assessment
Gestational age at assessment (weeks) 26.6 ± 3.7 30.5 ± 2.6 0.013*
Estimated fetal weight (g) 994 ± 496 1187 ± 328 0.30*
Estimated fetal weight centile 34 (29–66) 1 (0–3) < 0.001ω
Uterine arteries mean PI (z score) − 0.53 ± 1.77 2.60 ± 2.08 0.002*
Umbilical artery PI (z score) − 0.40 ± 0.32 1.27 ± 1.71 0.07*
Middle cerebral artery PI (z score) 0.13 ± 1.09 − 1.16 ± 0.99 0.027*
Cerebroplacental ratio (z score) − 0.06 ± 0.89 − 1.93 ± 1.6 0.027*
Ductus venosus PI (z score) − 1 ± 0.79 − 0.34 ± 1.29 0.44*
Maternal biochemical assessment
Gestational age at blood draw (weeks) 30 ± 1.8 31.3 ± 1.8 0.16*
Creatinine (mg/dl) 0.42 ± 0.07 0.69 ± 0.17 0.001*
Urea (mg/dl) 15.4 ± 4.2 40.4 ± 16.7 0.002*
Sodium (mEq/l) 138.3 ± 1.2 136.4 ± 2.1 0.048*
Potassium (mEq/l) 4.13 ± 0.21 4.61 ± 0.23 0.001*
AST (u/l) 17 (15–23) 25 (16–48) 0.16ω
ALT (u/l) 15 (9–21) 27 (14–65) 0.07ω
GGT (u/l) 10 (7–11) 19 (15–28) 0.013ω
Uric acid (mg/dl) 3.33 ± 0.43 6.09 ± 1.25 < 0.001*
Glucose (mg/dl) 75.5 ± 7.1 87.8 ± 19.7 0.13*
Triglycerides (mg/dl) 178.8 ± 67.7 260.6 ± 97.8 0.06*
Total cholesterol (mg/dl) 277.2 ± 50.1 241.9 ± 54 0.16*
Fibrinogen (g/l) 4.57 ± 0.98 3.44 ± 1.05 0.07*
Platelets  (103/l) 271.8 ± 70.6 209.1 ± 71.9 0.09*
Perinatal outcomes
Gestational age at delivery (weeks) 40.3 ± 1.1 32 ± 1.9 < 0.001*
Cesarean section 1 (16.7) 11 (78.6) 0.018ƒ
Male sex 2 (33.3) 6 (42.9) 0.69ƒ
Birthweight (g) 3531 ± 410 1287 ± 267 < 0.001*
Birthweight centile 58 (41–80) 0 (0–1) < 0.001ω
APGAR score 5 min < 7 0 (0) 1 (7.1) 0.50ƒ
Umbilical artery pH 7.20 ± 0.07 7.20 ± 0.09 0.97*
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preeclampsia. Previous studies have demonstrated physiologic complement activation in normal pregnancy 
as a regulatory mechanism to facilitate the clearance of fetoplacental debris and protect against  pathogens21–24. 
Further complement activation has been recognized in preeclampsia in the third trimester in line with heightened 
and more necrotic placental  debris25,26. This excessive complement activation was correlated with the severity of 
preeclampsia and its association with fetal growth  restriction27,28. Moreover, women with increased complement 
activation in early pregnancy were more likely to develop preeclampsia and adverse pregnancy  outcome29,30. 
In accordance with our findings, a proteomic approach on pooled plasma from patients with preeclampsia 
and/or fetal growth restriction has showed that most proteins from the complement and coagulation cascades 
were identified in isolated fetal growth restriction and depleted in preeclampsia with and without fetal growth 
 restriction14. Our group has also demonstrated that exposing endothelial cells in vitro to plasma from severe 
Figure 1.  (a) 2-dimensional and (b) 3-dimensional principal component analysis (PCA) scores plots. (c) 
Partial least squares discriminant analysis (PLS-DA) scores plot between components 1 and 2. The explained 
variance is shown in brackets. Controls (CT) are presented in green circles and preeclampsia cases (PE) in 
violet triangles. (d) Top 15 most important proteins contributing to groups separation identified through 
PLS-DA ranked by variable importance in projection (VIP) scores. The right heatmap shows mean intensity 
variable in the respective group, with red and green indicating high and low protein levels, respectively. VWF 
Von Willebrand factor, FN1 fibronectin, SERPINA6 corticosteroid-binding globulin, TF serotransferrin, ITIH3 
inter-alpha-trypsin inhibitor heavy chain H3, GPX3 glutathione peroxidase 3, FETUB FETUIN-B, ACTB actin, 
cytoplasmic 1, IGHG3 immunoglobulin heavy constant gamma 3, FCN3 ficolin-3, C4A complement C4-A, 
PAPPA pappalysin-1, SERPIND1 heparin cofactor 2, CFP properdin, GC vitamin D-binding protein.
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preeclampsia resulted in high deposition of the terminal complement pathway product known as membrane 
attack complex. This deposition was even stronger when the plasma was drawn from patients with HELLP syn-
drome and remained present at 6 weeks  postpartum31.
The complement system is a conserved host defense system traditionally known for protecting against bacte-
rial infection. Complement activation cascade leads to chemotaxis, immune-complex clearance and finally, the 
formation of membrane attack complex and cell lysis. Targeting excessive complement activation, particularly 
the terminal complement complex may be an effective strategy to prolong pregnancy in women with severe 
 preeclampsia32. Of note, there are recent therapeutic options that block complement activation like eculizumab 
and ravulizumab which inhibit C5 and others blocking the cascade at different levels and thus preventing the 
formation of membrane attack  complex33,34. Interestingly, eculizumab, which is already an approved treatment 
for both paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, was utilized success-
fully as a temporizing treatment in a unique case of severe  preeclampsia34,35. Our group has also demonstrated 
that blocking the membrane attack complex deposition on endothelial cells in vitro was achievable by adding 
 eculizumab31.
In parallel to the complement pathway activation, the coagulation gets also initiated which in turn triggers 
platelet  activity36. Activated platelets contribute to inflammation, immune responses and atherogenesis besides 
their central role in  hemostasis37–39. They aggregate at the site of endothelial cell erosion, stimulating thrombus 
formation and promoting atherothrombotic  disease37. Targeting these pathway by low molecular weight heparin 
or aspirin has failed as a treatment option once preeclampsia is  diagnosed1,40.
Our results show that other pathophysiological pathways are also significantly enriched in early-onset severe 
PE, including staphylococcus aureus infection, pertussis and systematic lupus erythematosus which constitutes 
a known risk factor for  preeclampsia41. These 3 pathways are all related to inflammatory processes and were 
enriched on the expenses of activated complement components C2 and C3. Preeclampsia has long been pro-
posed as an excessive maternal inflammatory response to  pregnancy42, since a systematic inflammatory profile 
similar to sepsis has been observed in  preeclampsia43, which could be a cause or a consequence of generalized 
endothelial  dysfunction44. Moreover, the most affected tissue in preeclampsia is maternal endothelium which is 
an integral part of the inflammatory  network45. Additionally and in harmony with our observation of comple-
ment activation in preeclampsia, an accumulating evidence showed extensive cross-talk between inflammation 
and the complement  system46 as well as the coagulation cascade, whereby coagulation affects considerably the 
inflammatory activity and vice  versa47.
Our analysis demonstrated additionally other significantly different proteins in early-onset severe preec-
lampsia compared to controls. Fetuin-B is a protease inhibitor and a member of the fetuin family implicated in 
diverse functions, including osteogenesis and bone resorption, regulation of the insulin and hepatocyte growth 
factor receptors, and response to systemic  inflammation48. Vitamin D-binding protein belongs to the albumin 
gene family and is able to bind the various forms of vitamin  D49. Fibronectin type III domain is an evolution-
ary conserved protein domain that is widely found in animal  proteins50. Inter-alpha-trypsin inhibitor heavy 
Table 2.  Univariate analysis results, 17 proteins were significantly different in preeclampsia vs controls after 
false discovery rate correction (q-value < 0.05).




Mean (SD) p-value q-value Preeclampsia/controls
P06681 Complement C2 (C2) 0.500 (0.245) − 0.214 (0.247) < 0.0001 0.0008 Down
Q9UGM5 Fetuin-B (FETUB) 0.649 (0.175) − 0.278 (0.479) < 0.0001 0.0008 Down
P02774 Vitamin D-binding protein (GC) 0.551 (0.128) − 0.236 (0.492) < 0.0001 0.0020 Down
P02751 Fibronectin type III domain containing (FN1) − 0.766 (0.419) 0.328 (0.426) < 0.0001 0.0020 Up
Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) − 0.692 (0.463) 0.297 (0.399) 0.0001 0.0030 Up
P04275 Von Willebrand factor (VWF) − 0.783 (0.467) 0.336 (0.483) 0.0001 0.0030 Up
P08185 Corticosteroid-binding globulin (SERPINA6) 0.744 (0.289) − 0.319 (0.482) < 0.0001 0.0030 Down
O75636 Ficolin-3 (FCN3) 0.626 (0.345) − 0.268 (0.398) 0.0002 0.0030 Down
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2) − 0.550 (0.255) 0.236 (0.348) 0.0004 0.0063 Up
P22352 Glutathione peroxidase 3 (GPX3) − 0.658 (0.327) 0.282 (0.491) 0.0005 0.0073 Up
P01042 Kininogen-1 (KNG1) 0.472 (0.306) − 0.202 (0.385) 0.0013 0.0192 Down
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 (ITIH1) − 0.442 (0.193) 0.189 (0.393) 0.0016 0.0215 Up
P27918 Properdin (CFP) 0.553 (0.228) − 0.237 (0.505) 0.0019 0.0231 Down
P01024 Complement C3 (C3) 0.391 (0.208) − 0.168 (0.362) 0.0025 0.0286 Down
P02760 Protein AMBP (AMBP) − 0.487 (0.273) 0.209 (0.519) 0.0046 0.0431 Up
P00740 Coagulation factor IX (F9) SERPIND1 − 0.336 (0.185) 0.144 (0.436) 0.0046 0.0431 Up
P60709 Actin, cytoplasmic 1 (ACTB) − 0.632 (0.516) 0.271 (0.589) 0.0044 0.0431 Up
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chains are main components together with AMBP protein of inter-alpha-trypsin inhibitors which function as 
Figure 2.  (a) Unsupervised hierarchical clustering based on the top 17 proteins selected from univariate 
analysis performed using Metaboanalyst 4.0 (http://www.metab oanal yst.ca/). A z-score transformation was 
performed on the intensity of each protein across all samples and each sample z-score is displayed in the 
heatmap. Proteins (in rows) and samples (in columns) are clustered by Euclidean distance and Ward linkage. 
(b) Protein–Protein Interaction network for these 17 proteins obtained using STRING database 11.00 (https 
://strin g-db.org/). Nodes represent proteins and edges interaction between proteins. The thickness of the edge 
indicates the degree of confidence prediction of the interaction. Only interactions with a high confidence score 
(> 0.7) were considered. F9 coagulation factor IX, C3 complement C3, CFP properdin, VWF Von Willbrand 
factor, KNG1 kininogen-1, FETUB fetuin-B, AMBP protein AMBP, ITIH1 inter-alpha-trypsin inhibitor heavy 
chain H1, C2 complement C2, SERPINA6 corticosteroid-binding globulin; FN1 fibronectin type III domain 
containing, ACTB actin, cytoplasmic 1, ITIH2 inter-alpha-trypsin inhibitor heavy chain H2, GPX3 Glutathione 
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protease inhibitors and have a role in inflammatory  response51. Corticosteroid-binding globulin is a member 
of the serine protease inhibitor family and is implicated in steroid transport and  delivery52. Ficolin-3 consists 
of a collagen-like domain and a fibrinogen-like domain and has lectin activity thereby it can activate the com-
plement pathway aiding in host defense through the activation of the lectin  pathway53. Glutathione peroxidase 
3 functions in the detoxification of hydrogen peroxide, its lower activity both in the placenta and in maternal 
blood has been associated with severe  PE54,55. Properdin is the only known positive regulator of complement 
activation that stabilizes the alternative pathway  convertases56. Overall, most of these proteins are connected 
to the complement activation directly or indirectly through protease inhibition. It is well known that plasma 
Table 3.  Kyoto encyclopedia of genes and genome (KEGG) enrichment analysis of different proteins in 
preeclampsia vs controls. F9 coagulation factor IX, C3 complement C3, VWF Von Willbrand factor, KNG1 
kininogen-1, C2 complement C2, ACTB Actin, cytoplasmic 1.
Pathway Count in gene set
Proteins involved
False discovery rateIncreasing in preeclampsia Decreasing in preeclampsia
Complement and coagulation 
cascades 5 of 78 F9, VWF KNG1, C3, C2 3.17e−07
Staphylococcus aureus infec-
tion 2 of 51 C3, C2 0.021
Pertussis 2 of 74 C3, C2 0.029
Systemic lupus erythematosus 2 of 94 C3, C2 0.034
Platelet activation 2 of 123 VWF, ACTB 0.045
Figure 3.  An illustration of the complement and coagulation cascades (homosapiens) from Kyoto Encyclopedia 
of Genes and Genome (KEGG) (https ://www.genom e.jp/kegg-bin/show_pathw ay?hsa04 610). A total of 5 (out of 
78) proteins were significantly enriched. Proteins that showed significantly lower and higher concentrations in 
preeclampsia are shown in red and blue respectively.
8
Vol:.(1234567890)
Scientific Reports |         (2021) 11:3048  | https://doi.org/10.1038/s41598-021-82733-z
www.nature.com/scientificreports/
Figure 4.  Representative microphotographs of the C5b-9 deposits (red) on endothelial cells in vitro (blue-
labeled nuclei) induced by incubation with plasma from healthy pregnancies (controls, n = 4) and pregnancies 
complicated by preeclampsia (PE, n = 4). The bar chart represents the quantification of C5b-9 deposits. 
Whiskers represent the mean ± standard deviation. All the controls samples are within the normal range 
whereas the four pregnant women with PE show significant complement activation (*p < 0.05).
Figure 5.  Representative microphotographs of the VWF deposits (red) on endothelial cells in vitro (blue-
labeled nuclei) induced by incubation with plasma from healthy pregnancies and pregnancies complicated by 
preeclampsia. The bar chart represents the quantification of average VWF deposits. Whiskers represent the 
mean ± standard deviation. **p < 0.01 by Student’s t-test compared to controls.
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protease inhibitors control a wide variety of physiological functions including blood coagulation, complement 
activation and aspects of the inflammatory  response57.
This study has some strengths and limitations that merit a comment. We included prospectively a well char-
acterized homogenous group of early-onset severe preeclampsia associated with fetal growth restriction, with 
no history of diabetes, autoimmune, renal or coagulation disorders. Furthermore, maternal blood samples were 
collected directly after confirmed preeclampsia diagnosis and at matched gestational age in controls and were 
processed and stored meticulously. In addition, our proteomic results were validated by quantifying C5b-9 and 
VWF deposits on endothelial cells exposed to activated plasma from an independent set of patients. However, we 
acknowledge the relatively small sample size included in this study and the need for investigating the identified 
pathways in other preeclampsia phenotypes. Besides, angiogenic factors that have been demonstrated to play a 
key role in preeclampsia and endothelial  dysfunction58 were not detected by our approach. This is partly because 
different detection methods were used, angiogenic factors are usually detected by antibody-based  techniques59 
which are specific to one single protein at a time and have lower detection limits than mass spectrometry based 
proteomics approaches.
Perspectives
Preeclampsia is considered to be responsible for up to 20% of the 13 million preterm births each year with high 
neonatal and long-term morbidity and  mortality60. Given the high morbidity and mortality associated with 
severe cases of preeclampsia, any therapeutic strategy that allowed to avoid maternal complications and prolong 
pregnancy would have a clear benefit for the health of mothers and fetuses. Likewise, the implementation of 
these strategies would also have a clear economic impact for the national health system by reducing unnecessary 
hospital costs from caesarean sections and prolonged hospitalization in intensive care units. Our approach has 
identified the pathophysiological pathways involved in early-onset severe preeclampsia that could provide a better 
understanding of underlying etiology and reveal potential therapeutic targets for this phenotype of preeclampsia. 
Further research is warranted to allow the development of effective therapeutics that target complement without 
compromising its role in host  defense32.
Methods
Study population. This was a nested case–control study within the project “Targeting endothelial dysfunc-
tion in highly prevalent diseases—PIE15/00027”. We included prospectively singleton pregnancies with a diag-
nosis of early-onset severe preeclampsia associated with fetal growth restriction who attended the Departments 
of Maternal–Fetal Medicine at BCNatal (Barcelona, Spain) between July 2016 and December 2017. Preeclamp-
sia was defined as high blood pressure (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 
90 mmHg on two occasions, at least four hours apart) with proteinuria (≥ 300 mg/24 h or protein/creatinine 
ratio ≥ 0.3) developed after 20 weeks of  gestation61,62. Early-onset cases refer to those that needed elective deliv-
ery before 34 weeks of gestation indicated for severe  preeclampsia9, which was considered upon presenting one 
or more of the following severity  criteria62: blood pressure ≥ 160 mmHg systolic or ≥ 110 mmHg diastolic on 
two occasions at least 4 h apart, thrombocytopenia (< 100,000/mm3), impaired liver function (elevated blood 
concentrations of liver enzymes to twice normal concentration and/or severe persistent right upper quadrant or 
epigastric pain unresponsive to medication and not accounted for by alternative diagnoses), progressive renal 
insufficiency (serum creatinine concentration > 1.1 mg/dl), pulmonary edema, new-onset cerebral or visual dis-
turbances. Pregnancy termination was by labor induction or cesarean section upon obstetric indication. Fetal 
growth restriction was defined as estimated fetal weight and birthweight below the 10th centile associated with 
either abnormal cerebroplacental ratio (< 5th centile) or abnormal uterine arteries mean pulsatility index (> 95th 
centile), or birthweight below the 3rd centile. Uncomplicated pregnancies with normotensive mothers and an 
appropriate for gestational age fetus-defined as estimated fetal weight and birthweight above the 10th centile- were 
randomly selected from our general population to be included as controls and matched with cases by maternal 
age, ethnicity, pre-gestational body mass index and gestational age at maternal blood draw (± 2 weeks). Esti-
mated fetal weight and birthweight centiles were calculated according to local  standards63. In all pregnancies, 
gestational age was calculated based on the crown-rump length at first trimester  ultrasound64. Pregnancies with 
chromosomal/structural anomalies or intrauterine infection were excluded. The history of pregestational diabe-
tes, autoimmune, renal or coagulation disorders were also considered excluding criteria. The study was conducted 
in accordance with the principles of the Helsinki declaration. The study protocol has been approved by the local 
ethics committee (HCB/2015/0585) and participating patients provided their written informed consent.
Data collection. The following data were recorded upon enrollment: maternal age, ethnicity, pregestational 
body mass index, chronic hypertension, parity, obstetric history, mode of conception and smoking status.
Additionally, estimated fetal weight and feto-placental Doppler assessment was achieved in all the study 
participants. Ultrasound studies were performed using a Siemens Sonoline Antares (Siemens Medical Systems, 
Malvern, PA, USA) or a Voluson 730 Expert (GE Medical Systems, Milwaukee, WI, USA) with 6–4-MHz linear 
curved-array probes. Estimated fetal weight was calculated using the Hadlock  formula65 and centile based on local 
reference  curves63. Fetoplacental Doppler examination followed standardized  guidelines66 included the uterine 
 arteries67, the umbilical  artery68, the fetal middle cerebral  artery68 and the ductus  venosus69 with the calculation 
of the cerebroplacental  ratio70. Maternal biochemical profile was also assessed at the time of maternal blood draw 
including the evaluation of renal (creatinine, urea, sodium, potassium) and liver (aspartate aminotransferase, 
alanine aminotransferase, gamma glutamyl transferase) function, uric acid, glucose, triglycerides, total choles-
terol, fibrinogen and platelets count.
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At the time of delivery, gestational age, birthweight, birthweight centile, Apgar scores, umbilical artery pH, 
admissions to the neonatal intensive care unit and perinatal mortality were recorded.
Maternal blood sampling. Peripheral maternal blood was obtained by venipuncture within 24–48 h of 
preeclampsia diagnosis and at matched gestational age for controls. The samples were incubated for 30 min at 
room temperature to allow clotting and subsequently centrifuged at 1500×g for 10 min at 4 °C to separate the 
serum from clots. Thereafter, serum samples were transferred to acetonitrile treated tubes and immediately 
stored at − 80 °C until assayed.
Proteomic analysis. Before proteomic analysis, the depletion of the seven most abundant serum proteins 
(Albumin, Immunoglobulin G, antitrypsin, Immunoglobulin A, transferrin, haptoglobin and fibrinogen) was 
performed using the Human-7 Multiple Affinity Removal Spin cartridge from Agilent Technologies, to increase 
the number of identified proteins. Afterwards, samples were processed for tandem mass tag (TMT) before acqui-
sition on a nanoscale liquid chromatography coupled to tandem mass spectrometry (nano LC–MS/MS) analysis 
with LTQ-Orbitrap Velos Pro from Thermo Fisher. Protein identification/quantification was performed on Pro-
teome Discoverer software version 1.4.0.288 (Thermo Fisher Scientific) by Multidimensional Protein Identifica-
tion Technology. On initial proteomic analysis, readers were blinded to patient’s status. Detailed methodology is 
provided as Supplementary Information.
Validation of the proteomic results. To evaluate the activation of the complement and coagulation cas-
cades, we assessed the deposits of C5b-9 complement complex and VWF on endothelial cells in vitro utilizing 
samples from an independent set of 4 healthy pregnancies and 4 cases of early-onset severe preeclampsia. Serum 
and plasma samples were obtained by centrifugation of nonanticoagulated blood and citrated blood (3000×g, 
15 min), respectively, within 6 h of extraction. All samples were aliquoted and stored at − 80 °C until they were 
used, avoiding freeze/thaw cycles.
To assess C5b-9 deposits, we obtained activated plasma by adding control sera to patient citrated plasma 
(1:1) using a modified technique than the one described by Noris et al.71. The human dermal microvascular 
endothelial cell line [HMEC-1] (American Type Culture Collection) was seeded on glass coverslips and used 
 confluent72. HMEC-1 were washed with test medium (HBSS without calcium or magnesium, 0.5% BSA; Life 
Technologies) and activated or not with 10 mM ADP (Sigma-Aldrich) (10 min, 37 °C). Cells were then incu-
bated (4 h) with activated plasma diluted with test medium (1:2). Control samples were obtained by mixing 
healthy plasma from donors with pooled sera from controls. Cultures were then washed and fixed. For C5b-9 
immunostaining, cells were treated with 2% BSA (1 h) and incubated with a rabbit anti-human complement 
C5b-9 complex (Calbiochem).
To assess VWF deposits, HMEC-1 were exposed to MCDB131 (Gibco-BRL, Madrid, Spain) supplemented 
with 20% sera from the patients under study or from their respective controls. Confluent cells were then washed 
(PBS, Gibco), fixed (PFA 4%, Electron Microscopy Sciences, Hatfield, PA, USA), permeabilized (Triton X-100 
0,025% Sigma-Aldrich, St Louis, MO, USA), blocked (1% BSA for 30 min) and incubated with a specific antibody 
against human VWF (Dako, Denmark).
Then, in both assessments (C5b-9 and VWF), incubation with an Alexa-594 conjugated rabbit secondary 
antibody (Molecular Probes, NY, USA) and 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI, Sigma-
Aldrich, St Louis, MO, USA) for nuclei staining was performed. Micrographs were captured by fluorescent 
microscopy (Leica DM4000B) through a video camera (Leica DFC310FX) and analyzed using Fiji (ImageJ, 
Bethesda, Rockville, MD, USA)73. A total of 20 photographs were randomly obtained from each preparation. The 
area covered by fluorescent C5b-9 or VWF labelling was calculated and expressed as the average fold increase. 
All samples were tested at least three times.
Statistical analysis. Clinical data were analyzed with the statistical software STATA 14.2 (StataCorp. 2015. 
Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). Categorical data are presented as per-
centages and continuous data as mean ± standard deviation or median (interquartile range) according to their 
distribution (which was assessed for normality using the Kolmogorov–Smirnov test). Statistical analysis for con-
tinuous variables included the use of student t-tests for normally distributed data or Mann Whitney U tests in 
the rest. Fisher exact test was used for categorical variables. All reported p-values are 2 sided. Differences were 
considered significant when p < 0.05.
For proteomics data, statistical approach was performed using Metaboanalyst 4.0 (http://www.metab oanal yst.
ca/). Initially, a multivariate modelling was applied including the use of unsupervised methods such as PCA, and 
supervised methods like PLS-DA and OPLS-DA. A variable importance in projection (VIP) plot, which is a visual 
representation of the importance of the particular proteins in discriminating the groups of interest, is provided. 
Secondly, for each protein a univariate Student’s t-test was performed and Benjamini–Hochberg method was used 
to adjust p values for multiple testing with consideration of 5% false discovery rate. An additional unsupervised 
HCA was performed based on the univariate results. Last, differential pathways were identified by PPI networks 
using STRING database 11.00 (https ://strin g-db.org/)74 and enrichment analysis using Kyoto Encyclopedia of 
Genes and Genome (KEGG)  database75. Detailed statistical approach is provided as Supplementary Data.
For C5b-9 and VWF deposits, the percentages of area covered were calculated as mean ± standard devia-
tion. Statistical analysis was performed with raw data using Student’s t test for paired samples by the statistical 
software SPSS (IBM Corp. Released 2016. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM 
Corp). Results were considered statistically significant when p < 0.05.
All methods were carried out in accordance with relevant guidelines and regulations.
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Data availability
The proteomics quantification data reported in this study are available as supplementary information.
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